Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients with PSMA-Positive Conventionally Negative Pelvic Lymphadenopathy
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, GU (ONC), Radiation Oncology (RADONC)
Current Status: Open
Phase: II
Principal Investigator: Baine, Michael
Contact Information:
Micki Bethea, BS
+1 402-559-8011
mbethea@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07237269?term=NCT07237269&viewType=Card&rank=1
Summary
Primary: Determine the impact of enhanced ADT (abiraterone/prednisone + ADT) vs standard ADT on 5-year failure-free survival (FFS) in patients with PSMA-positive, conventionally node-negative pelvic lymphadenopathy.
Secondary: Compare acute/chronic toxicities and patient-reported outcomes (IPSS, FACT P); evaluate progression-free survival, cancer-specific survival, overall survival, and metastasis-free survival at 5 years.
Exploratory: Model PSA-based tumor growth (g-rate) and regression (d-rate); correlate blood HO-1 levels with efficacy/toxicity; biobank blood for future biomarkers.